Systemic iodine absorption after preoperative antisepsis using povidone-iodine in cataract surgery - An open controlled study

Dermatology

Volumn 212, Issue SUPPL. 1, 2006, Pages 41-46

  Below, H ^a   Behrens Baumann, W ^b   Bernhardt, C ^b   Volzke H ^a   Kramer, A ^a   Rudolph, P ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Eye antisepsis; Povidone iodine; Systemic absorption; Thyroid function

Indexed keywords

IODINE; POVIDONE IODINE; TOPICAL ANTIINFECTIVE AGENT;

ABSORPTION; ADULT; AGED; ANTISEPSIS; ARTICLE; CATARACT EXTRACTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PREOPERATIVE CARE; TOPICAL DRUG ADMINISTRATION;

ABSORPTION; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, LOCAL; ANTISEPSIS; CATARACT EXTRACTION; FEMALE; HUMANS; IODINE; MALE; MIDDLE AGED; POVIDONE-IODINE; PREOPERATIVE CARE;

EID: 33745257291     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000089198     Document Type: Conference Paper

References (38)

1. Kramer A, Behrens-Baumann W: Antisepsis versus antimicrobial chemotherapy and indications for eye antisepsis; in Kramer A, Behrens-Baumann W (eds): Antiseptic Prophylaxis and Therapy in Ocular Infections. Basel, Karger, 2002, pp 14-27.
2. Behrens-Baumann W, Augustin AJ, Dick B, et al: Guidelines on prophylaxis and therapy of endophthalmitis. Hyg Med 2003; 28: 447-459.
3. Speaker MG, Binder CA, Menikoff JA: Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991; 98: 1769-1775.
4. Kranabitl HP, Bichler A: Prophylaxe der Ophthalmia neonatorum. Hyg Monitor 2001; 7: 2-3.
5. Isenberg SJ, Apt L, Campeas D: Ocular application of povidone-iodine. Dermatology 2002; 204(suppl1):92-95.
6. Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA, et al: A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol 2002; 134: 681-688.
7. Hansmann F, Kramer A, Ohgke H, Strobel H, Geerling G: Polyhexamethylbiguanid (PHMB) zur präoperativen Antisepsis bei Kataraktoperation. Ophthalmologe 2004; 101: 377-383.
8. Miňo de Kaspar H, Engelbert M, Klauss V, Kampik A: Colonization of the conjunctiva with Propionibacterium acnes before and after application of povidone iodine before intraocular surgery. Ophthalmologe 1998; 95: 438-441.
9. Binder CA, Miňo de Kaspar H, Klauss V, Kampik A: Preoperative infection prophylaxis with 1% povidone-iodine solution based on the example of conjunctival staphylococci. Ophthalmologe 1999; 96: 663-667.
10. Hara J, Yasuda F, Higashitsutsumi M: Preoperative disinfection of the conjunctival sac in cataract surgery. Ophthalmologica (Basel) 1997; 211(suppl 1):62-67.
11. Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA, et al: A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol 2002; 134: 681-688.
12. Wilhelm F, Jendral G, Bredehorn T, Dunker G, Wilhelms D, Kramer A: Antimicrobial decontamination of corneal donor material: infection prevention and quality assurance. Ophthalmologe 2001; 98: 143-146.
13. Müller G, Kramer A: In vitro action of combinations of selected antimicrobial agents and adult bovine articular cartilage (sesamoid bone). Chem Biol Interact 2003; 145: 331-336.
14. Bolton L, Oleniacz W, Constantine B, et al: Repair and antibacterial effects of topical antiseptic agents in vivo; in Maibach H, Lowe I (eds): Models in Dermatology 2. Basel, Karger, 1985, pp 145-158.
15. Rudolph P, Reimer K, Mlynski G, Reese M, Kramer A: Nose compatibility of local antiinfectives - An in vitro model using ciliated epithelium. Hyg Med 2000; 25: 500-503.
16. Kramer A, Below H, Behrens-Baumann W, Müller G, Rudolph P, Reimer K: New aspects of the tolerance of the antiseptic povidone-iodine in different ex vivo models. Dermatology 2001; 204(suppl 1):86-91.
17. Kramer A, Behrens-Baumann W: Prophylactic use of topical anti-infectives in ophthalmology. Ophthalmologica (Basel) 1997; 211(suppl 1):68-76.
18. Behrens-Baumann W, Augustin AJ, Dick B, Fabian E, Huber-Spitzy V, Klauss V, Kramer A, Pitten F-A, Pleyer U, Zeitz J: Leitlinie zur Prophylaxe und Therapie von Endophthalmitiden. Hyg Med 2003; 28: 447-459, revised version 2005;30:342-362.
19. Bauch K: Epidemiology of functional autonomy. Exp Clin Endocrinol Diabetes 1998; 106(suppl 4):16-22.
20. Völzke H, Lüdemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U, Meng W: The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803-810.
21. Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros NG: Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998; 8: 83-100.
22. Sandell EB, Kolthoff IM: Chronometric catalytic method for the determination of micro quantities of iodine. J Am Chem Soc 1934; 56: 1426.
23. Sandell EB, Kolthoff IM: Micro determination of iodine by a catalytic method. Mikrochim Acta 1937; 1: 9-25.
24. Lorenz-Wawschinek O, Tiran B, Eber O, Langsteger W: Photometric determination of iodine in urine. Exp Clin Endocrinol 1994; 102: 57-58.
25. Zöllner H, Kramer A, Hampel R: Screening for deficiency of iodine (in German). GIT Labor Med 1995; 18: 330-332.
26. International Council for the Control of Iodine Deficiency Disorder: Indicator for assessing IDD status. IDD Newslett 1999; 15: 33-39.
27. International Council for the Control of Iodine Deficiency Disorder: Standardization of ultrasound and urinary iodine determination for assessing iodine status. IDD Newslett 2000; 16: 19-23.
28. Zöllner H, Als C, Gerber H, Hampel R, Kirsch G, Kramer A: Screening for iodine deficiencyiodide concentration or creatinine quotient in random urine. GIT Lab J 2001; 3: 138-139.
29. WHO, UNICEF, ICCIDD: Progress towards the elimination of iodine deficiency disorders (IDD). WHO Doc WHO/NHD/99.4. Geneva, WHO, 1999.
30. WHO, UNICEF, ICCIDD: Assessment of the iodine deficiency disorders and monitoring their elimination. WHO Doc WHO/NHD/01.1. Geneva, WHO, 2001.
31. Delange F, de Benoist B, Bürgi H, ICCIDD Working Group: Determining median urinary iodine concentration that indicates adequate iodine intake at population level. Bull WHO 2002; 80: 633-636.
32. Schicha H, Facorro U, Schürnbrand P, Schreivogel I, Emrich D: Frequency of iodine contamination in a thyroid clinic. Mol Med 1980; 4: 177-181.
33. Böckers M, Klee W, Bräuninger W, Bork K: Das Hyperthyreoserisiko durch Lokaltherapie mit PVP-Iod. Akt Dermatol 1986; 12: 155-157.
34. Reinwein D, Benker G, König MP, Pinchera A, Schatz H, Schleusener H: Clinical aspects of hyperthyroidism in areas with different iodine supply. Schweiz Med Wochenschr 1987; 117: 1245-1255.
35. Grasso L, Maxia PL, Bartalena L, Murtas ML, Taberlet A, Martino E: Iodine contamination in subjects admitted to a general hospital. J Endocrinol Invest 1992; 15: 307-308.
36. Gutekunst R, Magiera U, Teichert HM: Iodine deficiency in Germany. Med Klin 1993; 88: 525-528.
37. Scriba PC, Gärtner R: Risiken der Jodprophylaxe? Dtsch Med Wochenschr 2000; 125: 671-675.
38. Richter R, Below H, Kadow I, Kramer A, Müller C, Fusch C: Effect of topical 1.25% PVPiodine eyedrops used for prophylaxis of ophthalmia neonatorum on renal iodine excretion and TSH level. Pediatrics, in press.